New York, April 30, 2025 (GLOBE NEWSWIRE) -- Muscular Dystrophy Association (MDA) applauds the U.S. Food and Drug Administration (FDA) approval of IMAAVYTM (nipocalimab-aahu) for the treatment of people ages 12 and older who are living with antibody positive (AChR+ or MuSK+) generalized myasthenia gravis (gMG). Learn more about this approval in Johnson & Johnson’s news release here. This milestone marks another significant advancement for the more than 100,000 people living with gMG in the U.S. gMG is a chr ...